How many 8-K filings has Anebulo Pharmaceuticals, Inc. filed?

Anebulo Pharmaceuticals, Inc. (ANEB) has 12 8-K (Current Event Report) filings on record, spanning Jun 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Anebulo Pharmaceuticals, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Anebulo Pharmaceuticals, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Anebulo Pharmaceuticals, Inc. (ANEB) — 8-K Filings

All 8-K filings from Anebulo Pharmaceuticals, Inc.. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

Anebulo Pharmaceuticals Files 8-K — Dec 22, 2025 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on December 22, 2025, reporting other events and financial statements. The filing details the company's principal exe
Anebulo Pharmaceuticals Files 8-K — Sep 12, 2025 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on September 12, 2025, reporting other events and financial statements. The filing details the company's principal ex
Anebulo Pharmaceuticals Files 8-K — Jul 23, 2025 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on July 23, 2025, reporting other events and financial statements. The filing details the company's principal executi
Anebulo Pharmaceuticals Files 8-K — Apr 15, 2025 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on April 15, 2025, reporting an event that occurred on April 11, 2025. The filing is categorized under 'Other Events'
Anebulo Pharmaceuticals Files 8-K — Apr 14, 2025 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on April 14, 2025, reporting events as of April 11, 2025. The filing includes amendments to its Articles of Incorpora
Anebulo Pharmaceuticals Reports Director/Officer Changes & Shareholder Votes — Apr 7, 2025 Risk: medium
Anebulo Pharmaceuticals, Inc. filed an 8-K on April 7, 2025, reporting events as of April 4, 2025. The filing indicates a departure of directors or certain offi
Anebulo Pharma Files 8-K: Material Agreement & Delisting Notice — Feb 24, 2025 Risk: high
Anebulo Pharmaceuticals, Inc. filed an 8-K on February 24, 2025, reporting a material definitive agreement and a notice of delisting or failure to satisfy listi
Anebulo Pharmaceuticals to Acquire Neuro-Bio Ltd. for $10M — Feb 12, 2025 Risk: medium
Anebulo Pharmaceuticals, Inc. announced on February 11, 2025, that it has entered into a definitive agreement to acquire all outstanding equity interests of Neu
Anebulo Pharmaceuticals Files 8-K: Material Agreement, Equity Sales — Dec 23, 2024 Risk: medium
On December 22, 2024, Anebulo Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported unregistered sales of equity securit
Anebulo Pharmaceuticals Files 8-K — Oct 17, 2024 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on October 17, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
Anebulo Pharmaceuticals Files 8-K — Jul 22, 2024 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on July 22, 2024, reporting other events and financial statements. The filing does not contain specific details about
Anebulo Pharmaceuticals Files 8-K — Jun 17, 2024 Risk: low
Anebulo Pharmaceuticals, Inc. filed an 8-K on June 17, 2024, reporting an event on June 13, 2024. The filing indicates the company's principal executive offices

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX